BioRestorative Therapies posts new investor deck

BioRestorative Therapies, Inc. filed a current report to let investors know it has made an updated corporate presentation available.

Accepted by SEC EDGAR 08/14/2025 - 05:08 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

BioRestorative Therapies, Inc. filed a current report to let investors know it has made an updated corporate presentation available. The presentation may be used at conferences and investor meetings and is accessible on the company’s website as well as attached as Exhibit 99.1. The company specifies that this presentation is being furnished under a disclosure item rather than formally filed, meaning it is not subject to certain Exchange Act liability provisions and is not automatically incorporated into other securities filings unless specifically referenced.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BioRestorative Therapies (BRTX) disclose in this 8-K?

The company disclosed that it has made an updated corporate presentation available, which may be used at conferences and investor meetings and is furnished as Exhibit 99.1.

Where can investors access BioRestorative Therapies’ updated corporate presentation?

Investors can view the updated corporate presentation on BioRestorative Therapies’ website at www.biorestorative.com and in the 8-K as Exhibit 99.1.

Is the BioRestorative Therapies presentation considered filed with the SEC?

No. The company states that the presentation is being furnished, not filed, so it is not deemed filed for purposes of Section 18 of the Exchange Act.

Does BioRestorative Therapies consider the presentation material for investment decisions?

The company states that furnishing the presentation does not constitute a determination or admission that the information is material or complete, or that investors should rely on it before making investment decisions.

What exhibit number contains the BioRestorative Therapies presentation?

The updated corporate presentation is included as Exhibit 99.1, with the cover page interactive data file identified as Exhibit 104.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false000150549700015054972025-08-142025-08-14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 14, 2025

BioRestorative Therapies, Inc.

(Exact name of registrant as specified in its charter)

Nevada		001-37603		30-1341024
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

40 Marcus Drive Melville, New York		11747
(Address of principal executive offices)		(Zip code)

Registrant's telephone number, including area code (631) 760-8100

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value	BRTX	NASDAQ Capital Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On August 14, 2025, BioRestorative Therapies, Inc. (the “Company”) made available an updated corporate presentation (the “Presentation”) that may be used by the Company in connection with presentations at conferences and investor meetings.  The Presentation can be found on the Company’s website, www.biorestorative.com.  The  Presentation is furnished as Exhibit 99.1 hereto.

The information in the Presentation is being furnished, not filed, pursuant to this Item 7.01. Accordingly, the information in the Presentation will not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.  The furnishing of the information in this Current Report on Form 8-K with respect to the Presentation is not intended to, and does not, constitute a determination or admission by the Company that the information in this Current Report on Form 8-K with respect to the Presentation is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Number	Description
99.1	Presentation Materials
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BIORESTORATIVE THERAPIES, INC.
Dated:  August 14, 2025	By:	/s/ Robert Kristal
		Robert Kristal
		Chief Financial Officer